Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (CHE) yesterday and set a price target of $535.00. The company’s shares closed last Tuesday at $437.16.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 15.3% and a 67.2% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Community Health, The Ensign Group, and Addus Homecare.
Chemed has an analyst consensus of Moderate Buy, with a price target consensus of $535.00, implying a 16.3% upside from current levels. In a report issued on April 20, RBC Capital also maintained a Buy rating on the stock with a $535.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $513.75 and a one-year low of $316.17. Currently, Chemed has an average volume of 128K.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CHE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the following segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.
